What is the difference between trametinib and dabrafenib?

Trametinib (Trametinib) are two drugs commonly used to treat malignant melanoma, non-small cell lung cancer, thyroid cancer and other cancers. They are often used together to achieve better therapeutic effects. They are all targeted therapeutic drugs that mainly inhibit the proliferation and survival of tumor cells by targeting mutated signaling pathways, but they have different mechanisms of action.

Trametinib mainly acts onMEK (mitogen-activated protein kinase) signaling pathway, inhibiting the activity of MEK protein in this pathway. MEK is a key component in the RAS-MAPK signaling pathway and is involved in the regulation of cell proliferation and survival. Trametinib works by reducing the proliferation and spread of malignant melanoma cells. Dabrafenib mainly acts on BRAF (B-Raf protein kinase) mutations. In some patients with malignant melanoma, the BRAF gene is mutated, leading to abnormal activation, thereby promoting the proliferation of tumor cells. By inhibiting the activity of BRAF mutant protein, dabrafenib can block this signaling pathway, thereby reducing the proliferation of melanoma cells.

The original drug of Trametinib has been launched in China and is included in the scope of medical insurance, but it may only be available to patients who meet the indications. The price of 2 mg*30 tablets is more than RMB 10,000. The original drug of Trametinib sold overseas, with the price of 2 mg*30 tablets, is more than RMB 7,000 (the price may fluctuate due to exchange rates). There are also generic trametinib drugs produced in other countries overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of a 2mg*30 tablet of a generic drug produced by a Laos pharmaceutical factory is more than 2,000 yuan (the price may fluctuate due to the exchange rate).